Telangana-based Sai Parenteral’s Limited has received final approval from the capital markets regulator, Securities and Exchange Board of India (SEBI) for its initial public offering (IPO).

The Company had filed its IPO papers with Sebi on September 30, 2025.

The IPO consists of a fresh up to Rs 285 crore and an offer-for-sale up to 3,500,000 shares by investors selling shares – Vikasa India EIF I Fund, Tilokchand Punamchand Ostwal, Devendra Chawla, Bhanwar Lal Chandak, Sreelekha Ganta, Padma Guntupalli, Vijay Gondi, Ideas and Journeys Private Limited, Bhautik Mukund Shah and Nilesh Pravinchandra Doshi.

The proceeds from its fresh issuance worth Rs 110.7.08 crore will be utilised for capacity expansion and upgradation of manufacturing facilities, Rs 18 crore for establishing a new R&D centre, Rs 20 crore for repayment / prepayment of certain outstanding borrowings, Rs 33.3 crore for working capital requirements and Rs 36 crore investment in wholly owned subsidiary, Sai Parenteral’s Pte Limited (Singapore) in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia), and general corporate purposes. 

The company is a diversified pharmaceutical formulations company with capabilities in research, development and manufacturing. The company is in the business of branded generic formulations, contract development and manufacturing organisation (CDMO) products and services for the domestic and international markets. The company’s portfolio includes formulation products across various therapeutic segments like cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology with offerings across dosage forms such as injectables, tablets, capsules, liquid orals and ointments. 

In the injectables segment, the company has capability in sterile manufacturing for critical care and penicillin-based therapies, offering delivery systems that include dry powder injections, pre-filled syringes, ampoules, and vials.

The company manufactures and sells Branded Generic Formulations to a diverse customer base, including central and state government agencies, pharmaceutical companies, public and private hospitals and super stockists in the domestic market. 

It started its export business in Fiscal 2023 after acquiring two internationally accredited manufacturing units in Hyderabad, Telangana. The company exports its products to regulated and semi-regulated markets of Australia, New Zealand, Southeast Asia, Middle East and Africa through distributors. The company’s CDMO business includes comprehensive solutions on product development, validation batches, stability studies, dossier compilation, international regulatory filings and commercial manufacturing. 

Hella Infra Market IPO

Hella Infra Market made a confidential DRHP filing with Sebi.